Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. O'Reilly on Tarextumab Combinations for Metastatic Pancreatic Cancer

Eileen O'Reilly, MD
Published: Thursday, Jan 26, 2017



Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses tarextumab combinations for patients with pancreatic cancer.

Tarextumab is a monoclonal antibody, explains O’Reilly. A phase II randomized trial was conducted following a phase Ib evaluation of combining tarextumab with gemcitabine and nab-paclitaxel (Abraxane) in patients with untreated metastatic pancreatic cancer. It was shown that the drugs can be safely combined, leading to the phase II trial.

Co-primary endpoints included overall survival and looking for outcomes in patients with phase II/III high biomarker expression, based on the preclinical data suggesting tarextumab may have heightened activity.

In the overall group there was no difference in outcome for the addition of tarextumab to gemcitabine and nab-paclitaxel, explains O’Reilly. This, however, gives the opportunity to investigate why this outcome has occurred.
 


Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses tarextumab combinations for patients with pancreatic cancer.

Tarextumab is a monoclonal antibody, explains O’Reilly. A phase II randomized trial was conducted following a phase Ib evaluation of combining tarextumab with gemcitabine and nab-paclitaxel (Abraxane) in patients with untreated metastatic pancreatic cancer. It was shown that the drugs can be safely combined, leading to the phase II trial.

Co-primary endpoints included overall survival and looking for outcomes in patients with phase II/III high biomarker expression, based on the preclinical data suggesting tarextumab may have heightened activity.

In the overall group there was no difference in outcome for the addition of tarextumab to gemcitabine and nab-paclitaxel, explains O’Reilly. This, however, gives the opportunity to investigate why this outcome has occurred.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x